Gateway Chemist Vaccination Centre

• All adults aged 65 years and over
• Residents in a care home for older adults
• Persons aged 6 months to 64 years who are immunosuppressed
• Frontline health and social care workers
• Persons aged 12 to 64 years who are household contacts of people with immunosuppression
• Persons aged 16 to 64 years who are carers  and staff working in care homes for older adults.

This include those who turn 65 years old by 31th March 2024 who are eligible for a vaccination at any point in the campaign. Those who are admitted to an older adult care home or become immunosuppressed by 31 March are considered eligible as well.

The JCVI also advised that primary course vaccination for individuals in the above cohorts who have not had any previous doses should be offered. They should receive a single dose of COVID-19 vaccine during the campaign period.

Immunosuppression due to disease or treatment, including patients undergoing chemotherapy leading to immunosuppression, patients undergoing radical radiotherapy, solid organ transplant recipients, bone marrow or stem cell transplant recipients, HIV infection at all stages, multiple myeloma or genetic disorders affecting the immune system (e.g. IRAK-4, NEMO, complement disorder, SCID).

Individuals who are receiving immunosuppressive or immunomodulating biological therapy including, but not limited to, anti-TNF, alemtuzumab, ofatumumab, rituximab, patients receiving protein kinase inhibitors or PARP inhibitors, and individuals treated with steroid sparing agents such as cyclophosphamide and mycophenolate mofetil.

Individuals treated with or likely to be treated with systemic steroids for more than a month at a dose equivalent to prednisolone at 20mg or more per day for adults.

Anyone with a history of haematological malignancy, including leukaemia, lymphoma, and myeloma.

Those who require long term immunosuppressive treatment for conditions including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, scleroderma and psoriasis.

Some immunosuppressed patients may have a suboptimal immunological response to the vaccine (see Immunosuppression and HIV).